BioSpace News Archive

Business

STYR Labs Appoints Pete Plamann As President To Bring High-Level Expertise In Consumer Engagement To Leadership Team

STYR Labs announces the appointment of Pete Plamann as President. Plamann joins the STYR Labs leadership team, bringing high level development and implementation expertise to lead the company’s continued growth and aggressive expansion.

October 14, 2017

·

3 min read

Policy

GSK’s Shingrix Containing Agenus’ QS-21 Stimulon Adjuvant Receives Marketing Authorization From Health Canada

Agenus announced today that Health Canada granted marketing authorization to Glaxo’s shingles vaccine, Shingrix, that contains Agenus’ proprietary immune adjuvant QS-21 Stimulon adjuvant.

October 14, 2017

·

4 min read

Policy

Orexigen Announces Favorable Decision From U.S. District Court In Patent Litigation, Confirming Exclusivity For Contrave Through 2030

Orexigen announced today that the United States District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against Actavis for three patents for Contrave (naltrexone HCl / bupropion HCl extended release) with exclusivity through 2030.

October 14, 2017

·

6 min read

BioMidwest

Aratana Therapeutics Announces Launch Of ENTYCE (Capromorelin Oral Solution)

Aratana Therapeutics announced the Company is making ENTYCE (capromorelin oral solution) commercially available to veterinarians in the United States for appetite stimulation in dogs.

October 14, 2017

·

8 min read

FDA

Janssen Announces FDA Approval Of STELARA (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis

Janssen Biotech announced today that the FDA has approved an expanded indication for STELARA (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

October 14, 2017

·

11 min read

Lone Star Bio

Genprex Commences Initial Public Offering And Sets Price

Genprex today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share.

October 14, 2017

·

4 min read

Biotech Beach

DermTech Presents Two Abstracts at Fall Clinical Dermatology Conference

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the presentation of two abstracts at the 36th Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada.

October 14, 2017

·

2 min read

Biotech Beach

Tandem Diabetes Care Announces Pricing of $16.2 Million Underwritten Public Offering of Common Stock and Warrants

Tandem Diabetes Care today announced the pricing of an underwritten public offering.

October 14, 2017

·

5 min read